DANIEL BAKER, ATC, LAT
Athletic Trainer at Briarcrest Ave, Memphis, TN
License number
Tennessee 2000003568
Category
Restorative Service Providers
Type
Athletic Trainer
Address
Address
6286 Briarcrest Ave #110, Memphis, TN 38120
Phone
(901) 259-1600
Personal information
See more information about DANIEL BAKER at radaris.comName
Address
Phone
4993 Shadowbend Cir, Clarksville, TN 37043
4879 Decatur Hwy, Ten Mile, TN 37880
Professional information
Principal Product Manager At Medtronic Spinal &Amp; Biologics
Position:
Principal Product Manager at Medtronic Spinal & Biologics, Senior Product Manager at Medtronic Spine & Biologics
Location:
Greater Memphis Area
Industry:
Medical Devices
Work:
Medtronic Spinal & Biologics
- Memphis, TN since Apr 2013
-
Principal Product Manager
Medtronic Spine & Biologics
since Nov 2010
-
Senior Product Manager
Medtronic
Oct 2008 - Nov 2010
-
Product Manager
Medtronic
Nov 2006 - Oct 2008
-
Associate Product Manager
Medtronic Sofamor Danek
Aug 2004 - Nov 2006
-
Marketing Specialist
Medtronic Sofamor Danek
Sep 2003 - Aug 2004
-
Contractor
Education:
Ashford University 2008 - 2010
MBA, Masters of Business Administration Nicholls State University 2004 - 2004
N/A, Travel Abroad Program The University of Memphis 1998 - 2004
BBA, Int'l Business/Mktg. Mgmt.
MBA, Masters of Business Administration Nicholls State University 2004 - 2004
N/A, Travel Abroad Program The University of Memphis 1998 - 2004
BBA, Int'l Business/Mktg. Mgmt.
Daniel Baker, Memphis TN - ATC
Specialties:
Athletic Training
Address:
6286 Briarcrest Ave SUITE 110, Memphis 38120
(901) 259-1600 (Phone)
(901) 259-1600 (Phone)
Languages:
English
Lysophosphatidic Acid Analogs And Inhibition Of Neointima Formation
US Patent:
2004020, Oct 14, 2004
Filed:
Apr 9, 2004
Appl. No.:
10/821739
Inventors:
Gabor Tigyi - Memphis TN, US
Daniel Baker - Memphis TN, US
Chunxiang Zhang - Memphis TN, US
Daniel Baker - Memphis TN, US
Chunxiang Zhang - Memphis TN, US
International Classification:
A61K031/739
US Classification:
514/054000
Abstract:
The phospholipid growth factor lysophosphatidic acids (LPAs) containing unsaturated fatty acids (18:1, 18:2 and 20:4) and fatty alcohols containing hydrocarbon chains with more than 4 carbons were capable of inducing a rapid formation of neointima, an initial step in the development of atherosclerotic plaque. LPAs with saturated fatty acids did not induce neointima formation. A Peroxisome Proliferator-Activated Receptors gamma (PPAR)-specific agonist Rosiglitasone also induced a profound formation of neointima. GW9662, a selective and irreversible antagonist of PPAR, abolished LPA- and Rosiglitazone-induced neointima formation, indicating that LPA-induced neointima formation requires the activation of PPAR. These data suggest that LPA analogs that bind to but do not activate downstream signaling of PPAR or antagonists of PPAR that inhibit PPAR signaling would be useful in the prevention and/or treatment of neointima formation and atherosclerosis.
Lpa Receptor Agonists And Antagonists And Methods Of Use
US Patent:
2005026, Nov 24, 2005
Filed:
Feb 28, 2005
Appl. No.:
11/067884
Inventors:
Duane Miller - Germantown TN, US
Gabor Tigyi - Memphis TN, US
James Dalton - Columbus OH, US
Vineet Sardar - Cordova TN, US
Don Elrod - College Station TX, US
Huiping Xu - Memphis TN, US
Daniel Baker - Memphis TN, US
Dean Wang - Memphis TN, US
Karoly Liliom - Budapest, HU
David Fischer - Plymouth MA, US
Tamas Virag - Memphis TN, US
Nora Nusser - Memphis TN, US
Gabor Tigyi - Memphis TN, US
James Dalton - Columbus OH, US
Vineet Sardar - Cordova TN, US
Don Elrod - College Station TX, US
Huiping Xu - Memphis TN, US
Daniel Baker - Memphis TN, US
Dean Wang - Memphis TN, US
Karoly Liliom - Budapest, HU
David Fischer - Plymouth MA, US
Tamas Virag - Memphis TN, US
Nora Nusser - Memphis TN, US
International Classification:
A61K031/675, A61K031/663, C07F009/28
US Classification:
514091000, 514102000, 548112000, 558158000
Abstract:
The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.
Diverse Lead Compound Autotaxin Inhibitors
US Patent:
8343934, Jan 1, 2013
Filed:
Jun 30, 2010
Appl. No.:
12/828053
Inventors:
Daniel Lee Baker - Memphis TN, US
Elton Jeffrey North - Memphis TN, US
Elton Jeffrey North - Memphis TN, US
Assignee:
University of Memphis - Memphis TN
International Classification:
A61K 31/655, C07C 309/52, C07C 245/10
US Classification:
514 219, 514150, 514576, 514577
Abstract:
Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.
Mechanism-Based Inactivators Of Autotaxin
US Patent:
8022239, Sep 20, 2011
Filed:
Oct 2, 2009
Appl. No.:
12/572921
Inventors:
Daniel Lee Baker - Memphis TN, US
Louis Edward Montedonico - Memphis TN, US
Louis Edward Montedonico - Memphis TN, US
Assignee:
The University of Memphis Research Foundation - Memphis TN
International Classification:
C07F 9/147
US Classification:
558210, 558 89, 558206
Abstract:
A novel class of compounds to inactivate autotaxin enzymes is provided. Such compounds include mono- and di-fluoromethylphenyl C-Cphosphodiesters and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds are non-cytotoxic, and can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of producing such novel compounds are encompassed within this invention as well as methods of inactivating autotaxin to certain degrees therewith.
Lpa Receptor Agonists And Antagonists And Methods Of Use
US Patent:
6875757, Apr 5, 2005
Filed:
Mar 19, 2001
Appl. No.:
09/811838
Inventors:
Duane D. Miller - Germantown TN, US
Gabor Tigyi - Memphis TN, US
James T. Dalton - Columbus OH, US
Vineet M. Sardar - Memphis TN, US
Don B. Elrod - College Station TX, US
Huiping Xu - Memphis TN, US
Daniel L. Baker - Memphis TN, US
Dean Wang - Memphis TN, US
Karoly Liliom - Budapest, HU
David J. Fischer - Cordova TN, US
Tamas Virag - Memphis TN, US
Nora Nusser - Memphis TN, US
Gabor Tigyi - Memphis TN, US
James T. Dalton - Columbus OH, US
Vineet M. Sardar - Memphis TN, US
Don B. Elrod - College Station TX, US
Huiping Xu - Memphis TN, US
Daniel L. Baker - Memphis TN, US
Dean Wang - Memphis TN, US
Karoly Liliom - Budapest, HU
David J. Fischer - Cordova TN, US
Tamas Virag - Memphis TN, US
Nora Nusser - Memphis TN, US
Assignee:
University of Tennessee Research Foundation - Knoxville TN
International Classification:
A61K031/661, C07F009/06
US Classification:
514119, 558170
Abstract:
The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.
Acetal Phosphate-Derived Lpa Mimics, Ppargamma Activators, And Autotaxin Inhibitors
US Patent:
2006027, Nov 30, 2006
Filed:
May 6, 2006
Appl. No.:
11/418561
Inventors:
Duane Miller - Memphis TN, US
Gabor Tigyi - Memphis TN, US
Yuko Fujiwara - Memphis TN, US
Daniel Baker - Memphis TN, US
Michelle Walker - Alexandria VA, US
Gangadar Durgam - Memphis TN, US
Gabor Tigyi - Memphis TN, US
Yuko Fujiwara - Memphis TN, US
Daniel Baker - Memphis TN, US
Michelle Walker - Alexandria VA, US
Gangadar Durgam - Memphis TN, US
International Classification:
A61K 31/665
US Classification:
514099000, 549216000
Abstract:
Disclosed are compositions that modulate the effects of extracellular LPA receptors, the intracellular PPARĪ³ receptor, and autotaxin, and methods for their use.
Pipemidic Acid Derivative Autotaxin Inhibitors
US Patent:
8497371, Jul 30, 2013
Filed:
Oct 26, 2010
Appl. No.:
12/912604
Inventors:
Daniel Lee Baker - Memphis TN, US
Adrienne Hoeglund - Collierville TN, US
Adrienne Hoeglund - Collierville TN, US
Assignee:
University of Memphis Research Foundation - Memphis TN
International Classification:
C07D 471/04
US Classification:
544279
Abstract:
Novel and optimized classes of pipemidic acid derivative compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes of compounds exhibit exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.
Autotaxin Inhibitors
US Patent:
8268891, Sep 18, 2012
Filed:
Nov 13, 2008
Appl. No.:
12/270840
Inventors:
Daniel Lee Baker - Memphis TN, US
Assignee:
University of Memphis Research Foundation - Memphis TN
International Classification:
A61K 31/17, A61K 31/19, A61K 31/496
US Classification:
514580, 514279, 514284, 514339, 514354, 514585, 514656, 514755
Abstract:
Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include thioureas, diphenyldiazerenes, xanthenes, and isoindoles and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of inactivating autotaxin to certain degrees therewith such compounds are encompassed within invention as well.